Adolescence Obesity
Conditions
Keywords
Efsubaglutide Alfa, GLP-1 receptor agonist, Adolescent Obesity, weight loss
Brief summary
This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose administration in Chinese adolescent participants with obesity.
Detailed description
The prevalence of obesity in adolescents is rising and threatening physiological and psychological health. Different from adults with obesity, there is still no approved drug to manage the obesity in adolescents, In order to provide the therapeutical option earlier, the weight-reduction study in obese adolescents is planned. The primary objective of this Phase Ib study is to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of multiple doses of Efsubaglutide Alfa at different dose levels in Chinese adolescent participants with obesity. The secondary objectives include the evaluations of the pharmacodynamic (PD) effects, PK-PD relationship , and immunogenicity of multiple doses of Efsubaglutide Alfa at different dose levels. This randomized, double-blind, placebo-controlled, parallel-group study will enroll a total of 36 adolescent participants aged 12 to 17 years with obesity . 36 participants will be randomized in a 3:1 ratio to receive Efsubaglutide Alfa or placebo administered subcutaneously once weekly (QW) for up to 12 weeks. Safety will be monitored throughout the study by assessment of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESI), laboratory parameters, vital signs, and 12-lead electrocardiograms.
Interventions
DRUGEfsubaglutide Alfa placebo
Efsubaglutide Alfa placebo Injection Subcutaneous injection
DRUGEfsubaglutide Alfa 5 mg QW
Efsubaglutide Alfa Injection Subcutaneous injection
DRUGEfsubaglutide Alfa 10 mg QW
Efsubaglutide Alfa Injection Subcutaneous injection
Efsubaglutide Alfa Injection Subcutaneous injection
Sponsors
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Three dose cohorts (5 mg, 10 mg, 20 mg QW) with intra-cohort 3:1 active-to-placebo randomization; all cohorts include a dose-titration phase followed by atarget-dose 12-week maintenance period for 12 weeks treatment in total (including dose titration and dose maintenance period).
Eligibility
Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Informed consent must be obtained from the participant's parent or legally authorized representative and assent from the adolescent participant before any study-related procedures. * 2\. Adolescent participants aged ≥12 years and \<18 years (at the time of informed consent). * 3\. At screening, meet the obesity criteria defined in "WS/T586-2018 Screening for Overweight and Obesity among School-age Children and Adolescents". * 4\. Before screening, have been on dietary and exercise control alone for at least 3 months with \<5.0% reduction in body mass index (based on self-report or report by parent or legally authorized representative). * 5.Must be willing to follow the diet and exercise guidance and able to maintain such stable diet and exercise lifestyle during the study period. * 6\. Female participants of childbearing potential must have a negative serum pregnancy test at screening. * 7\. Able to understand all study procedures, willing to strictly comply with the study protocol, complete the study visits as scheduled, and finish the study.
Exclusion criteria
* 1\. Pre-pubertal participants (Tanner Stage I). * 2\. History of severe allergic reactions or suspected allergy to study drug or its ingredients. * 3\. Pregnant or lactating women; men or women of childbearing potential planning pregnancy or unwilling to use highly effective contraception throughout the study. * 4\. Use of weight-affecting medications before screening. * 5\. Known monogenic obesity, obesity caused by other diseases or medications, * 6\. Previously diagnosed Type 1 diabetes, Type 2 diabetes, or special types of diabetes; * 7\. history of severe hypoglycemia or recurrent symptomatic hypoglycemia (≥2 times within half a year). * 8\. Clinically significant gastric emptying abnormalities, severe chronic gastrointestinal diseases, long-term use of medications directly affecting gastrointestinal motility, or gastrointestinal surgery within 6 months prior to screening, deemed unsuitable for the study by the investigator. * 9\. History of malignancy within 5 years prior to screening, excluding clinically cured cervical intraepithelial neoplasia, squamous cell carcinoma, or basal cell carcinoma within 5 years. * 10\. Major surgery within 6 months prior to screening, or planned surgery during the study that may affect study completion or compliance; * 11\. history of bariatric surgery or planned bariatric surgery during the study (e.g., gastric bypass, gastric banding). * 12\. History of acute or chronic pancreatitis, symptomatic gallbladder disease at screening, history of pancreatic injury, or other high-risk factors for pancreatitis; or amylase or lipase \>2.0×ULN at screening. * 13\. Known or suspected drug/substance abuse at screening; positive HBsAg; * 14\. Positive HCV antibody with HCV RNA above the lower limit of detection; positive HIV antibody; positive Tp-Ab. * 15\. Currently receiving or received chronic (\>14 days) systemic glucocorticoid therapy within 3 months prior to screening, or evidence of severe active autoimmune disease that may require systemic glucocorticoid therapy within the next 12 months as judged by the investigator. * 16\. History of hyperthyroidism or hypothyroidism, or TSH \<1.0×LLN, or TSH \>1.5×ULN, or history of medullary thyroid carcinoma. * 17\. Serum calcitonin ≥50 ng/L (pg/mL) at screening; ALT \>3.0×ULN, or AST \>3.0×ULN, or total bilirubin \>2.0×ULN; eGFR \<60 mL/min/1.73 m² at screening; fasting triglycerides ≥5.64 mmol/L (500 mg/dL). * 18\. Blood donation and/or blood loss ≥400 mL or bone marrow donation within 3 months prior to screening, or presence of hemoglobinopathy, hemolytic anemia, sickle cell anemia, or hemoglobin \<118 g/L (ages 12-\<13 years), \<129 g/L (males ≥13 years), or \<114 g/L (females ≥13 years). * 19\. Participation in vaccine or medical device clinical trials within 3 months prior to screening, or any drug clinical trial within less than 3 months or 5 half-lives (whichever is longer). * 20\. History of moderate to severe depression, anxiety disorder, or severe psychiatric illness. * 21\. Any other condition that, in the opinion of the investigator, may affect the participant's safety or compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability: incidence of TEAEs, SAEs, and AESI | Throughout the study (up to Week 18) | Safety and tolerability assessed by monitoring treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESI) throughout the study |
| Pharmacokinetic (PK) characteristics at steady state following multiple doses | Throughout the study (up to Week 18) | PK parameters including plasma drug concentrations at steady state following multiple-dose administration of Efsubaglutide Alfa |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in body mass index (BMI) from baseline (absolute and percentage) | Week 12 | Change in BMI from baseline at Week 12, measured as absolute value and percentage change |
| Change in BMI from baseline over time (absolute and percentage) | Weeks 4, 8, and 12 | Change in BMI from baseline at Weeks 4, 8, and 12, measured as absolute value and percentage change |
| Change in fasting body weight from baseline (absolute and percentage) | Week 12 | Change in fasting body weight from baseline at Week 12, measured as absolute value and percentage change |
| Change in fasting body weight from baseline over time (absolute and percentage) | Weeks 4, 8, and 12 | Change in fasting body weight from baseline at Weeks 4, 8, and 12, measured as absolute value and percentage change |
| Change in waist circumference from baseline | Week 12 | Change in waist circumference from baseline at Week 12 |
| Change in hip circumference from baseline | Week 12 | Change in hip circumference from baseline at Week 12 |
| Change in waist-to-hip ratio (WHR) from baseline | Week 12 | Change in waist-to-hip ratio (WHR) from baseline at Week 12 |
| Change in waist-to-height ratio from baseline | Week 12 | Change in waist-to-height ratio from baseline at Week 12 |
| Proportion of participants achieving ≥5%, ≥10%, and ≥15% reduction in BMI and/or fasting body weight from baseline | Week 12 | — |
| Change in systolic blood pressure and diastolic blood pressure from baseline | Week 12 | — |
| Change in lipid levels(TC、HDL-C、LDL-C、TG) from baseline | Week 12 | — |
| Change in fasting blood glucose from baseline | Week 12 | — |
| Change in HbA1c from baseline | Week 12 | — |
| Change in fasting insulin from baseline | Week 12 | — |
| Change in blood uric acid from baseline | Week 12 | — |
| The correlation between Efsubaglutide Alfa Cmax, ss and BMI | Throughout the study (up to Week 18) | — |
| The correlation between Efsubaglutide Alfa AUC0-168h, ss and BMI | Throughout the study (up to Week 18) | — |
| Incidence, titer, and persistence of anti-drug antibodies (ADA) | Throughout the study (up to Week 18) | — |
| Incidence, titer, and persistence of neutralizing antibodies | Throughout the study (up to Week 18) | — |
Countries
China
Contacts
CONTACTQINGHUA WANG, M.D,Ph.D
Outcome results
None listed